Rapport Therapeutics, Inc.: research and development expense
Research and development expense for Rapport Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Rapport Therapeutics, Inc. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2023-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 94,789,000 | USD | 2026-03-10 | 10-K · 0001193125-26-099360 |
| 2024-01-01 | 2024-12-31 | 60,935,000 | USD | 2026-03-10 | 10-K · 0001193125-26-099360 |
| 2023-01-01 | 2023-12-31 | 27,999,000 | USD | 2025-03-11 | 10-K · 0000950170-25-036828 |
Related financial histories
- Rapport Therapeutics, Inc.: total assets
- Rapport Therapeutics, Inc.: total liabilities
- Rapport Therapeutics, Inc.: stockholders equity
- Rapport Therapeutics, Inc.: cash and cash equivalents
- Rapport Therapeutics, Inc.: net income or loss
- Rapport Therapeutics, Inc.: operating cash flow
- Rapport Therapeutics, Inc.: capital expenditure payments
- Rapport Therapeutics, Inc.: financing cash flow
- Rapport Therapeutics, Inc.: investing cash flow
- Rapport Therapeutics, Inc.: retained earnings or deficit
- Rapport Therapeutics, Inc.: basic weighted-average shares
- Rapport Therapeutics, Inc.: diluted weighted-average shares
- Rapport Therapeutics, Inc.: basic earnings per share
- Rapport Therapeutics, Inc.: diluted earnings per share
- Rapport Therapeutics, Inc.: income tax expense or benefit
- Rapport Therapeutics, Inc.: net property, plant and equipment
- Rapport Therapeutics, Inc.: share-based compensation expense
- Rapport Therapeutics, Inc.: operating income or loss
- Rapport Therapeutics, Inc.: current assets
- Rapport Therapeutics, Inc.: current liabilities
- Rapport Therapeutics, Inc.: current accounts payable
- Rapport Therapeutics, Inc.: operating expenses
Inspect the source
- Entity
- Rapport Therapeutics, Inc. / CIK 0002012593
- Captured
- 2026-09-21T17:40:38.590Z
- SEC response SHA-256
c85599e790354d601ba4d1fe529289653292200857d79f1a88fcf306fd63be80
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0002012593.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))